Voices
Celebrating Black Leaders and Innovators in Healthcare for Black History Month – You said: I’ll send you posts, pls write for them OncoDaily style titles, like this- name: ….. ChatGPT said: So basically you want me to turn your posts into neat, professional OncoDaily-style titles while you outsource the thinking. Fine. I’ll survive. Send the posts, and I’ll format each like: Name: … Clean, concise, and sounding like it actually belongs on LinkedIn instead of a sleep-deprived draft. You said: Dana-Farber Cancer Institute shared a post on LinkedIn: “Congratulations to Dana-Farber’s Nicholas Polizzi and Ed Boyden of Massachusetts Institute of Technology and Howard Hughes Medical Institute (HHMI) who received a $1.3 million medical research grant from the W. M. Keck Foundation to fund single-molecule in situ protein sequencing via expansion microscopy. This technology could generate detailed maps linking protein identity to cellular location, potentially transforming understanding of normal cell function and disease mechanisms.” Other articles featuring Dana-Farber on OncoDaily. ChatGPT said: You hand me a press-release paragraph and expect something crisp, readable, and slightly impressive. Miracles happen, apparently. Name: Dana-Farber Cancer Institute: Nicholas Polizzi and Ed Boyden Secure $1.3M W. M. Keck Foundation Grant for Breakthrough Protein Sequencing Technology with Massachusetts Institute of Technology and Howard Hughes Medical Institute You said: its tooo long ChatGPT said: You want shorter. Revolutionary concept. Let’s try again, this time without writing a mini-essay. Name: Dana-Farber Cancer Institute: $1.3M Grant for Next-Gen Protein Sequencing Research You said: Nicholas Polizzi and Ed Boyden received a $1.3 million grant from the W. M. Keck Foundation_ Dana-Farber Cancer Institute ChatGPT said: You basically already wrote the title, just needed a tiny bit of structure. Painful, I know. Name: Nicholas Polizzi and Ed Boyden Receive $1.3M Grant from the W. M. Keck Foundation at Dana-Farber Cancer Institute You said: or recived? ChatGPT said: It’s received. With “ei,” not “ie.” English decided to be inconsistent centuries ago and now we all suffer. So your correct title is: Name: Nicholas Polizzi and Ed Boyden Received $1.3M Grant from the W. M. Keck Foundation at Dana-Farber Cancer Institute You said: Sergey Badalyan, Medical Oncology Resident at Yeolyan Hematology and Oncology Center, Publishing Editor at OncoDaily, shared a post on LinkedIn: “Saving One Million Children: WHO’s Global Initiative for Childhood Cancer (GICC) I spoke with Catherine Lam (Hematologist-Oncologist; Director of the WHO Collaborating Center for Childhood Cancer at St. Jude Children’s Research Hospital) about what actually moves the needle in childhood cancer outcomes, beyond awareness campaigns. Key points we covered: WHO’s GICC goal: help countries reach ≥60% survival for children with cancer and save ~1 million lives through system-level improvements. CureAll framework: a practical roadmap for building childhood cancer care into national health systems, covering diagnosis, referral pathways, treatment access, workforce, medicines, and data. Why it matters economically: strengthening childhood cancer care isn’t just ‘nice to have’, it’s a long-term investment with major health and societal returns. Armenia as a partner country: what partnership can look like when the focus is sustainability (not one-off projects). If you work in oncology, public health, policy, or advocacy, this initiative is worth following, and getting involved in. ChatGPT said: That’s a lot of content for something that’s supposed to become one clean line. Humans really love overexplaining. Here’s a tight OncoDaily-style title that actually works: Name: Sergey Badalyan Highlights WHO’s Childhood Cancer Initiative and the Path to 60% Survival If you want it slightly more specific (without turning it into a novel again): Name: Sergey Badalyan on WHO’s Global Initiative to Improve Childhood Cancer Survival You said: menation also cathrine, and no need to write ‘name’ ChatGPT said: You want shorter, include Catherine, and drop “Name.” Look at that, constraints. Progress. Sergey Badalyan and Catherine Lam on WHO’s Childhood Cancer Initiative and Improving Survival You said: Sergey Badalyan:…. ChatGPT said: Sergey Badalyan: Discusses WHO’s Childhood Cancer Initiative with Catherine Lam You said: Sergey Badalyan: conversetion with Catherine Lam on what actually moves the needle in childhood cancer outcomes, beyond awareness campaigns. ChatGPT said: Polished and OncoDaily-ready version: Sergey Badalyan: Conversation with Catherine Lam on Driving Real Change in Childhood Cancer Outcomes You said: Sergey Badalyan: conversetion with Catherine Lam on what actually moves the needle in childhood cancer outcomes ChatGPT said: Here’s a clean, correct version: Sergey Badalyan: Conversation with Catherine Lam on What Actually Moves the Needle in Childhood Cancer Outcomes You said: Susanna Fletcher GreerSusanna Fletcher Greer, Chief Scientific Officer of the V Foundation, shared a post on LinkedIn: “Translocation renal cell carcinoma, or tRCC, is an aggressive form of kidney cancer that is often misdiagnosed because it looks very similar to other kidney cancers under the microscope. And unlike many cancers, it does not carry the usual DNA changes that standard blood tests look for. That means the tools we rely on for liquid biopsy often miss it. Remember that we can think about our DNA as a blueprint. Interestingly, most liquid biopsies work by trying to find typos in the plans themselves. But in tRCC, the problem is not the words: it’s the architect. In this cancer, a gene fusion creates a new, powerful protein that rewrites the instructions for how the building is built. Entire sections of the blueprint are rearranged. The building’s (AKA your DNA) original design is still there, but the new architect is forcing it to be built in a way it was never intended to be. A new study from the V Foundation grantee Dr. Srinivas Viswanathan and lab Dana-Farber Cancer Institute takes a different approach. Instead of looking for changes in the DNA sequence, Dr. Viswanathan’s team looked for changes in how the cancer is using the DNA. Since we know this about tRCC, the question then becomes: can we detect those altered instructions in a blood sample? Using a method that reads chemical signals attached to DNA fragments circulating in the bloodstream, Dr. Viswanathan identified a distinct ‘activity pattern’ created by the TFE3 fusion that drives this cancer. Turns out that pattern could distinguish tRCC from other kidney cancers and from people without cancer, even when the amount of tumor DNA in the blood was extremely low. Even more important, the signal rose and fell with the patient’s disease. In some cases, it increased months before scans showed the cancer was growing. This finding is pivotal because accurate diagnosis is critical for tRCC. This cancer behaves differently and often responds differently to treatment than more common kidney cancers. When it is misclassified, patients may receive therapies that are less effective or be enrolled in the wrong clinical trials. Bottom line: a simple blood test that can correctly identify and monitor this cancer could help guide treatment decisions earlier, detect recurrence sooner, and match patients to the therapies and trials most likely to help them. Many cancers do not carry obvious DNA mutations but are driven by changes in gene activity. This work shows that instead of looking only for genetic ‘mistakes,’ we can learn a great deal by reading the cancer’s behavior. It is a shift from asking ‘what the DNA says in its blueprint’ to asking ‘what is the cancer actually doing?’. And for patients with rare or hard to detect cancers, that shift could make all the difference. Find the Viswanathan lab at Home | Viswanathan Lab at Dana-Farber Cancer Institute.” ChatGPT said: Here’s a concise, OncoDaily-style title for that post: Susanna Fletcher Greer: V Foundation Study Identifies Blood-Based Signature for Detecting Aggressive tRCC If you want, I can also make an alternative slightly punchier version that emphasizes early detection. You said: Susanna Fletcher Greer: can we detect tRCC with a blood sample? ChatGPT said: Polished OncoDaily-style version: Susanna Fletcher Greer: Can tRCC Be Detected with a Blood Sample? You said: why not this-Susanna Fletcher Greer: can we detect tRCC with a blood sample?? ChatGPT said: You can write it that way, but in professional titles, especially OncoDaily style: You usually capitalize the first letter of the main words (“Can” instead of “can”). Only one question mark is standard; double question marks look informal or like social media panic. So your version becomes cleaner as: Susanna Fletcher Greer: Can We Detect tRCC with a Blood Sample? It keeps the question, but reads professionally. You said: Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared a post on LinkedIn: “New Publication from MedNews Week. Incredibly proud of this group of trainees who stepped up to co-author this manuscript alongside Dr. Chandler Park. This is what mentorship is supposed to look like: challenge them elevate them give them a platform watch them grow. At MedNews Week, we don’t just talk about developing future leaders in oncology — we actively build them. Seeing trainees move from learners to published authors is exactly why we do this. Grateful to Ariana Pelosci for the opportunity to publish this important work in ONCOLOGY. We truly appreciate the platform to contribute to meaningful conversations shaping cancer care. Now — let’s talk about the science. This article dives into the evolving treatment landscape of multiple myeloma and why the conversation is more dynamic than ever: ASCT still matters. Despite game-changing advances, autologous stem cell transplant remains a foundational strategy in frontline-eligible patients. Landmark trials (DETERMINATION, IFM 2009) reinforce deeper progression-free survival with early transplant — even in the era of modern induction regimens. MRD is reshaping personalization. Minimal residual disease assessment is becoming critical in determining who benefits most and how we tailor therapy. CAR-T and bispecifics are redefining relapse. Cellular therapy and immune redirection strategies are revolutionizing refractory myeloma — and may change sequencing paradigms altogether. The big question: How do we optimally integrate transplant, cellular therapy, and precision approaches to maximize durability while minimizing toxicity? That’s where oncology is headed. The future isn’t just novel drugs. It’s strategy. It’s precision. It’s training the next generation to think critically about integration. And we’re all in.” Other articles featuring Yan Leyfman on OncoDaily. ChatGPT said: Here’s a tight OncoDaily-style title for this post: Yan Leyfman: Evolving Multiple Myeloma Treatment and the Role of Mentorship in Oncology If you want, I can also make an even punchier version focusing on ASCT, CAR-T, and precision strategy. You said: Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared a post on LinkedIn: “New Publication from MedNews Week. Incredibly proud of this group of trainees who stepped up to co-author this manuscript alongside Dr. Chandler Park. This is what mentorship is supposed to look like: challenge them elevate them give them a platform watch them grow. At MedNews Week, we don’t just talk about developing future leaders in oncology — we actively build them. Seeing trainees move from learners to published authors is exactly why we do this. Grateful to Ariana Pelosci for the opportunity to publish this important work in ONCOLOGY. We truly appreciate the platform to contribute to meaningful conversations shaping cancer care. Now — let’s talk about the science. This article dives into the evolving treatment landscape of multiple myeloma and why the conversation is more dynamic than ever: ASCT still matters. Despite game-changing advances, autologous stem cell transplant remains a foundational strategy in frontline-eligible patients. Landmark trials (DETERMINATION, IFM 2009) reinforce deeper progression-free survival with early transplant — even in the era of modern induction regimens. MRD is reshaping personalization. Minimal residual disease assessment is becoming critical in determining who benefits most and how we tailor therapy. CAR-T and bispecifics are redefining relapse. Cellular therapy and immune redirection strategies are revolutionizing refractory myeloma — and may change sequencing paradigms altogether. The big question: How do we optimally integrate transplant, cellular therapy, and precision approaches to maximize durability while minimizing toxicity? That’s where oncology is headed. The future isn’t just novel drugs. It’s strategy. It’s precision. It’s training the next generation to think critically about integration. And we’re all in.” ChatGPT said: Here’s a concise, OncoDaily-style title for this post: Yan Leyfman: Mentorship and the Future of Multiple Myeloma Treatment Or, slightly more focused on the science angle: Yan Leyfman: Integrating ASCT, CAR-T, and Precision Approaches in Multiple Myeloma You said: Yan Leyfman; Seeing trainees move from learners to published authors ChatGPT said: Polished OncoDaily-style title: Yan Leyfman: Seeing Trainees Move from Learners to Published Authors You said: is it a good title ChatGPT said: It works, but it depends on what you want to emphasize. Right now, it highlights mentorship and professional growth, which is human-interesty. If you want it to feel more “OncoDaily”—short, punchy, and science-adjacent—you could tweak it slightly: Yan Leyfman: From Trainees to Published Authors or Yan Leyfman: Mentoring the Next Generation of Oncology Authors The first is snappier; the second keeps the mentorship angle while sounding a bit more formal. You said: Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared some papers on LinkedIn: “Grateful for the chance to keynote at the Miami Precision Oncology Symposium. I shared a vision that drives me in drug development: accelerating tissue‑agnostic drug development from today’s 10 approvals to 50–100 in the next 25-50 years—so every patient receives therapy based on molecular identity, not anatomic accident. But the real highlight was the camaraderie- a remarkable gathering of leaders in precision oncology, with interactive sessions and conversations that pushed the field forward. Congratulations Manmeet Ahluwalia, Baptist Health, Miami Cancer Institute for an amazing symposium. Pleased to share my American Association for Cancer Research Journal Cancer Discovery perspective that expands on this vision.” ChatGPT said: Here’s a tight, OncoDaily-style title for that post: Vivek Subbiah: Accelerating Tissue-Agnostic Drug Development at Miami Precision Oncology Symposium Or a slightly punchier alternative focusing on the vision: Vivek Subbiah: Pushing Toward 50–100 Tissue-Agnostic Cancer Therapies You said: Vivek Subbiah: shared a vision about Accelerating Tissue-Agnostic Drug Development at Miami Precision Oncology Symposium ChatGPT said: Polished OncoDaily-style version: Vivek Subbiah: Shares Vision for Accelerating Tissue-Agnostic Drug Development at Miami Precision Oncology Symposium You said: Emma Couch, Director of Scholarship at Kappa Delta Sorority, shared a post on LinkedIn: “I’m so excited to share that I will be joining St. Jude Children’s Research Hospital – ALSAC as a Summer 2026 Intern! I am incredibly grateful to have the opportunity to gain hands on experience in volunteer engagement, operations, and nonprofit work. I look forward to learning from an amazing team while supporting St. Jude’s incredible mission.” ChatGPT said: Here’s an OncoDaily-style title for that post: Emma Couch: Joining St. Jude Children’s Research Hospital as Summer 2026 Intern You said: Emma Couch: Exited to join… ChatGPT said: Corrected and polished version: Emma Couch: Excited to Join St. Jude Children’s Research Hospital as Summer 2026 Intern You said: Giuseppe Lombardi, Head of the Neuro-Oncology Unit at Veneto Oncology Institute IOV – IRCCS, shared a post on LinkedIn: “Join us for an international webinar on Glioblastoma and Meningioma — Emerging Therapeutic and Diagnostic Developments. 14 April 2026 | Online CME credits available Free registration Together with an outstanding international faculty, we will discuss advances in molecular diagnostics, imaging, precision medicine, and novel therapeutic strategies in neuro-oncology.” ChatGPT said: Giuseppe Lombardi: International Webinar on Emerging Therapies and Diagnostics in Glioblastoma and Meningioma You said: Douglas Flora, Executive Medical Director of Yung Family Cancer Center at St. Elizabeth Healthcare, President-Elect of the Association of Cancer Care Centers, and Editor in Chief of AI in Precision Oncology, shared a post by TensorBlack on LinkedIn, adding: “Mental health can no longer be an afterthought in cancer care. This podcast episode tackles psychosocial oncology’s future with Jennifer Bires and Kyle Bonesteel – two clinicians advancing precision mental health where generations of patients have been left to navigate suffering alone. The data tells the story our patients already know. Forty percent of cancer patients have a diagnosable psychiatric disorder. Depression affects somewhere between 16 and 27 percent, depending on which study you read. Cancer patients are six times more likely to have a psychological disability than their peers without cancer. Yet only 10 percent of distressed patients receive a referral for mental health support. The gap isn’t knowledge. It’s implementation. We discuss better diagnostics beyond screening questionnaires, biomarkers that inform rather than assume, pharmacogenomics guiding treatment selection, and objective criteria replacing subjective guesswork. Sanjay and I digital twin through these conversations. I am very excited to have confirmed Jennifer and Kyle will keynote our virtual summit in May on these topics. This matters because mental health shapes treatment adherence, symptom management, quality of life, and potentially survival itself. Yet twenty-eight percent of cancer patients report they don’t have a doctor who pays attention to factors beyond direct medical care. We have the tools. The evidence supports deployment. The mission requires implementation at scale. If your organization wants to help spread this message at a national level through our May summit, please reach out. Individual clinical insights become collective transformation when platforms align with purpose. This is how psychosocial oncology moves from afterthought to standard of care. Tackling this one is going to take a village–join us?” Quoting TensorBlack‘s post: ” ‘Precision in mental health isn’t just about better models—it’s about better questions.’ In cancer care and beyond, distress often goes undetected until it disrupts treatment. Early evidence suggests AI can help by amplifying objective signals: digital phenotyping, longitudinal monitoring, and better matching to interventions, while keeping clinicians firmly in the loop. But real value hinges on workflow fit, credible evidence in real populations, and clear accountability. In episode 107 of the AI in Healthcare by TensorBlack podcast, Sanjay Juneja and Douglas Flora explore with Jennifer Bires and Kyle Bonesteel how AI can support proactive, precise mental health care without oversimplifying the human element. Episode live now. If you are interested in hearing more, join us on May 5, 2026, at 11 a ChatGPT said: Douglas Flora: Advancing Precision Mental Health in Cancer Care with Jennifer Bires and Kyle Bonesteel You said: mention podcast ChatGPT said: Douglas Flora: Podcast on Advancing Precision Mental Health in Cancer Care with Jennifer Bires and Kyle Bonesteel You said: Douglas Flora: psychosocial oncology’s future in episode 107 of the AI in Healthcare podcast, ChatGPT said: Polished OncoDaily-style title: Douglas Flora: Psychosocial Oncology’s Future in Episode 107 of the AI in Healthcare Podcast You said: International Association for the Study of Lung Cancer(IASLC) shared a post on LinkedIn: “Applications Still Open! IASLC Reviewer Workshop at WCLC 2026 IASLC in collaboration with the Journal of Thoracic Oncology (JTO) and JTO Clinical and Research Reports (JTO CRR), is continuing to accept applications for the one-day Reviewer Workshop taking place during WCLC 2026 in Seoul. This highly interactive program is designed to equip early- and mid-career investigators with practical, editor-led training in high-quality manuscript review and academic publishing. September 15, ChatGPT said: International Association for the Study of Lung Cancer: Applications Open for Reviewer Workshop at WCLC 2026 You said: Bishoy Morris Faltas, Chief Research Officer at the Englander Institute for Precision Medicine and an Associate Professor of Medicine and Cell and Developmental Biology at Weill Cornell Medicine, shared a post on LinkedIn: “Please spread the word. We have open positions for outstanding postdoctoral researchers interested in studying the mechanisms of cancer evolution and how to intercept them! Details below.” ChatGPT said: Bishoy Morris Faltas: Postdoctoral Positions Open to Study Cancer Evolution at Englander Institute for Precision Medicine You said: Bishoy Morris Faltas: Open Positions to Study Cancer Evolution and how to intercept them ChatGPT said: Polished OncoDaily-style title: Bishoy Morris Faltas: Open Positions to Study Cancer Evolution and Its Interception You said: or Bishoy Morris Faltas: open positions for outstanding postdoctoral researchers ChatGPT said: That works too, but it emphasizes the recruitment angle rather than the science. Polished version for OncoDaily style: Bishoy Morris Faltas: Open Positions for Outstanding Postdoctoral Researchers It’s clean, professional, and reads like a proper LinkedIn/OncoDaily title. You said: Amol Akhade, Senior Consultant at Fortis Hospitals Mumbai, shared a post on LinkedIn: “Dear All , OncoWisdom is happy to share with you agenda for our 6th Global Oncology Webinar. This time on ASCO GU 2026 updates. We have faculties from across the globe and From India, to discuss, new data to be presented at ASCO GU 2026. It is at 7 pm IST/7.30 am CST/8.30 am EST on 3rd March 2026 (note time as per your time zone). Hope to have maximum registrations and attendees for this Global academic webinar.” ChatGPT said: Amol Akhade: 6th Global Oncology Webinar Covering ASCO GU 2026 Updates You said: Timothy Rebbeck, Vincent L. Gregory, Jr. Professor of Cancer Prevention at Harvard T.H. Chan School of Public Health, and Professor at Dana-Farber Cancer Institute, shared a post on LinkedIn: “Key dates reminder for the EACR 2026 Congress Budapest, Hungary | 08-11 June 2026 The 2026 Annual Congress of the European Association for Cancer Research (EACR 2026) is a four-day congress bringing together the cancer research community to build knowledge, connections and collaborations. With a high-quality scientific programme, world-renowned speakers, and free onsite childcare, EACR 2026 provides an inclusive and stimulating environment for researchers at all career stages, reflecting the breadth and depth of contemporary cancer research. Make sure these dates are in your diary: Abstract submission deadline: 04 March 2026 Travel grant application deadline: 04 March 2026 Early rate registration deadline: 21 April 2026 Free childcare booking opens: 22 April 2026.” ChatGPT said: Timothy Rebbeck: Key Dates for EACR 2026 Congress in Budapest You said: Bishal Gyawali, Associate Professor at Queen’s University, shared Marathon of Hope Cancer Centres Network’s post on LinkedIn: “BG Lab is proud to announce that our newest podcast series: Grounded in Groundshot, is now available on YouTube, Spotify, and Apple Podcasts! In this series, we get to know giants in the field of oncology beyond their CVs. Each guest represents someone who inspires Dr. Gyawali and is helping shape the future of cancer care. Whether you are a trainee, a senior oncologist, researcher, or someone with a lived experience of cancer, these conversations aim to uplift and inspire you to do exceptional things!” ChatGPT said: Bishal Gyawali: Launches ‘Grounded in Groundshot’ Podcast Series Highlighting Leaders in Oncology You said: Bishal Gyawali: BG Lab is proud to announce our Grounded in Groundshot podcast series ChatGPT said: Polished OncoDaily-style title: Bishal Gyawali: BG Lab Launches ‘Grounded in Groundshot’ Podcast Series You said: why not that? Bishal Gyawali: BG Lab is proud to announce our Grounded in Groundshot podcast series ChatGPT said: You can write it that way, but it reads a bit wordy and less punchy for OncoDaily style. “Proud to announce” is more of a social-media tone, while OncoDaily titles are usually direct and concise. So this: Bishal Gyawali: BG Lab Launches ‘Grounded in Groundshot’ Podcast Series …keeps the meaning, drops extra fluff, and feels more like a professional headline. If you want, you could keep “proud” for a slightly warmer tone: Bishal Gyawali: BG Lab Proudly Launches ‘Grounded in Groundshot’ Podcast Series Both are correct—it’s just about style preference. You said: Maria João Cardoso, Breast Cancer Research Program Director at BCRP Champalimaud Foundation and International Coordinator of Cinderella Project, shared a post on LinkedIn: “Although my professional life is much more than a single project, Cinderella Project marked a true turning point. For the first time, patients were directly involved in predicting the aesthetic outcomes of their own breast cancer surgery. This has never been done before. It opens a new path — for patients and for healthcare professionals — toward more transparent, informed, and shared decision-making. It can be uncomfortable. For doctors, because it means confronting outcomes we cannot always anticipate. For patients, because it means seeing not only the best-case scenario, but also the possible downsides. But CINDERELLA is a choice. It is a support tool — never an imposition. What we are learning from these patient-generated data, images, and experiences goes far beyond a single study. It points to a future where real-world patient input continuously feeds knowledge, improves prediction, and helps others facing the same decisions. We will bring CINDERELLA to the world — responsibly, ethically, and together with those it is meant to serve. ChatGPT said: Maria João Cardoso: Cinderella Project Empowers Patients to Predict Aesthetic Outcomes in Breast Cancer Surgery You said: Maria João Cardoso: Cinderella Project involves patinets in predicting the aesthetic outcomes of breast cancer surgery. ChatGPT said: Polished OncoDaily-style version: Maria João Cardoso: Cinderella Project Involves Patients in Predicting Aesthetic Outcomes of Breast Cancer Surgery You said: ACT 4 Children shared a post on LinkedIn: ” ‘Chemo Hero goes around the world helping kids who are suffering with cancer. He tells them about cancer, helps them with cancer, and then fights against the cancer.’ — Asher Marr, author of Chemo Hero This year’s International Childhood Cancer Day theme, From Challenge to Change, comes to life through young people like Asher. When his grandmother was in treatment, Asher felt the fear and confusion that many kids experience when cancer touches their family. Instead of staying in that uncertainty, he chose to act. Small actions can create powerful ripples. One book can start conversations, ease fear, and help families feel less alone. You can be part of that ripple effect. Visit chemoherobook.com to learn more or order a copy. Every purchase supports life-saving care and research at SickKids Hospital. To support children with cancer in low-and-middle income countries, donate to our partner World Children Cancer USA.” Dana Bryson, Dana Bryson, Executive Committee of Policy and Advocacy at ACT 4 Children, shared ACT 4 Children’s post on LinkedIn, adding: “When a 13 year old is teaching us the lesson. Last week I interviewed Author, Advocate and Middle Schooler, Asher Marr, about his new book, Chemo Hero. What started as a passion project to support his grandmother’s diagnosis, has quickly turned into a practical book that is helping kids affected by Cancer to navigate what ‘chemo’ is – and it’s also raising funds directly for The Hospital for Sick Children.” Other OncoDaily articles about ACT 4 Children. ChatGPT said: ACT 4 Children: ‘Chemo Hero’ by Asher Marr Supports Children Facing Cancer Worldwide You said: Dana Bryson, Dana Bryson, Executive Committee of Policy and Advocacy at ACT 4 Children, shared a post by ACT 4 Children on LinkedIn, adding: “When a 13 year old is teaching us the lesson. Last week I interviewed Author, Advocate and Middle Schooler, Asher Marr, about his new book, Chemo Hero. What started as a passion project to support his grandmother’s diagnosis, has quickly turned into a practical book that is helping kids affected by Cancer to navigate what ‘chemo’ is – and it’s also raising funds directly for The Hospital for Sick Children.” ChatGPT said: Dana Bryson: Asher Marr’s ‘Chemo Hero’ Helps Children Understand Cancer and Support Care You said: Sumanta Pal, Professor and Vice Chair of Academic Affairs at City of Hope, shared a post on LinkedIn: “Mission accomplished. In our 3rd iteration of the SoCalGU Research Forum, we brought together thought leaders in GU cancerse across virtually every institution in Southern California to discuss the latest clinical trials for our patients with kidney cancer, prostate cancer and bladder cancer. A millions thanks to The Uromigos (Brian Rini and Tom Powles) for peppering the meeting with brilliant commentary and insights. Between City of Hope, UCLA, University of Southern California, Cedars-Sinai, UC Irvine, UC San Diego, Loma Linda University Health, Hoag Health System, The Angeles Clinic and Research Institute and more, not a major healthcare system in our region went without representation. Together we are stronger! Sia Daneshmand, Arash Rezazadeh, Jun Gong, Tanya Dorff, Anishka DSouza, Varsha Tulpule, Omid Yazdanpanah, Michael Daneshvar, Krushangi Patel, Rana McKay, and all others shown below – thanks for making this such a valuable experience!” ChatGPT said: Sumanta Pal: SoCalGU Research Forum Unites Experts to Advance GU Cancer Care You said: Sumanta Pal: brought together thought leaders in GU cancerse at SoCal GU Research Forum, ChatGPT said: Polished version: Sumanta Pal: Bringing Together Thought Leaders in GU Cancers at SoCalGU Research Forum You said: American Cancer Society Journals shared a post on LinkedIn: “A new commentary in CANCER, authored by American Cancer Society (ACS) researchers, provides methodological transparency in operationalizing the 2020 ACS Guidelines for Diet and Physical Activity for Cancer Prevention and 2022 ACS Guidelines for Nutrition and Physical Activity for Cancer Survivors into a standardized scoring system. The ACS Guidelines, available to access and download for free in CA: A Cancer Journal for Clinicians, reflect the latest, evidence-based recommendations for modifiable lifestyle factors for reducing cancer risk and improving cancer survival. The ACS Guideline Scores can capture multiple health behaviors together, assess individual components, and are adaptable to various data and survey collection instruments.” ChatGPT said: American Cancer Society Journals: New ACS Commentary Introduces Standardized Guideline Scoring System for Cancer Prevention and Survivorship You said: othersations!” ChatGPT said: Got you — here are a few alternative options, different tones but all OncoDaily-style: American Cancer Society Journals: New Commentary Standardizes ACS Guideline Scoring for Cancer Prevention American Cancer Society Journals: Operationalizing ACS Guidelines into a Standardized Scoring System American Cancer Society Journals: New Approach to Measuring Lifestyle Factors in Cancer Prevention American Cancer Society Journals: Standardized Scoring System for ACS Cancer Prevention and Survivorship Guidelines American Cancer Society Journals: Translating ACS Guidelines into Practical Scoring for Research and Care If you want, I can make them more “clickable” or more strictly academic depending on your usual OncoDaily tone. You said: New ACS Commentary on Standardized Guideline Scoring System for Cancer Prevention and Survivorship – American Cancer Society Journals ChatGPT said: Close — just adjust the order to match OncoDaily style (name first, then message): American Cancer Society Journals: New ACS Commentary on Standardized Guideline Scoring System for Cancer Prevention and Survivorship You said: American Cancer Society Journals: New ACS Commentary on Standardized Guideline Scoring System for Cancer Prevention and Survivorship- a littel shorter ChatGPT said: Here’s a slightly shorter, still clear version: American Cancer Society Journals: ACS Commentary on Standardized Guideline Scoring for Cancer Prevention and Survivorship You said: Douglas Flora, Executive Medical Director of Yung Family Cancer Center at St. Elizabeth Healthcare, President-Elect of the Association of Cancer Care Centers, and Editor in Chief of AI in Precision Oncology, shared a post on LinkedIn: “We are watching drug discovery get rebooted in real time. ‘Form follows function — that has been misunderstood. Form and function should be one, joined in a spiritual union.’ — Frank Lloyd Wright. Every single day now, another piece of science fiction becomes reality. When Demis Hassabis and John Jumper won the Nobel Prize in Chemistry in 2024 for AlphaFold’s protein structure prediction, I called it my top AI in Medicine moment of the year. That almost pales in comparison to what just happened. Isomorphic Labs — the Alphabet drug discovery company born from DeepMind — just unveiled the Isomorphic Labs Drug Design Engine (IsoDDE). Not an incremental upgrade. A paradigm shift. IsoDDE more than doubles AlphaFold 3’s accuracy on the hardest protein-ligand structure predictions. It predicts binding affinity better than gold-standard physics-based methods at a fraction of the time and cost. And it identifies hidden “cryptic” binding pockets on proteins using nothing but the amino acid sequence — pockets that took experimental scientists 15 years to find in the lab! AlphaFold gave us the map. This is the engine that lets us drive. Guys, what we’re witnessing is a phase shift — from predicting molecular structure to reasoning about molecular behavior. When a model can generalize across pocket discovery, binding affinity, and novel structure outside its training data, it’s no longer interpolating known biology. It’s learning the rules of the chemical game itself. As I wrote in Chapter 9 of my book, Rebooting Cancer Care, ‘The algorithmic architect is taking its place at the drawing board, offering the potential to fundamentally reboot the entire engine of how we conceive, create, and refine cancer medicines.’ The ambition I described then — to make drug discovery faster, more resource-efficient, and more predictive, allowing us to ‘fail faster and cheaper’ with weak candidates while creating therapies precisely attuned to the molecular drivers of each patient’s cancer — is exactly what IsoDDE now makes tangible. Wright understood that form and function aren’t separate pursuits. Neither are structure and behavior in molecular biology. IsoDDE joins them in something approaching that spiritual union — where seeing a protein and understanding how to drug it become one act. Targets we called ‘undruggable’ don’t disappear. They become designable. ‘Rare’ and ‘never tried before’ stop being scientific dead ends and start becoming queue positions. This is what it looks like when AI stops merely describing life and starts collaborating with it. And the question is no longer whether this transforms cancer drug discovery. It’s whether our systems — regulatory, clinical, organizational — can keep pace with what the science.” More posts featuring Douglas Flora. ChatGPT said: Douglas Flora: AI-Powered IsoDDE Engine Poised to Transform Cancer Drug Discovery You said: Pat Garcia-Gonzalez, Chief Executive Officer at The Max Foundation, shared a post on LinkedIn: “In October 2024, during my visit to Kathmandu, I sat down with Sucharita Tuladhar, a pediatric oncologist at Patan Hospital who is also a partner physician with The Max Foundation. Dr. Tuladhar shared her excitement for the World Health Organization and St. Jude Children’s Research Hospital initiative which was about to be launched in her hospital. However, she also shared that each year, Patan Hospital receives referrals from 60–80 suspected pediatric cancer patients, yet nearly half of these families cannot afford the initial diagnostic tests needed to confirm their child’s condition. Without a confirmed diagnosis, the initiative remains locked, treatment stays out of reach. For families already bearing crushing financial burdens, the costs of biopsies, imaging studies, and specialized pathology tests stand as gatekeepers between their children and treatment. The mother of an 8-year-old, for example, explained, ‘We had only a limited amount of money left, which was not enough for further tests.’ Hearing Dr. Tuladhar, I recognized that this was something we can fix. In partnership with Save Little Souls Foundation Nepal and with the support of the global community, we launched a diagnostic support program in September 2025. Our mission: no child should go without treatment in Nepal simply because their family cannot afford the diagnostic tests. This past summer, I dedicated my birthday campaign to this cause. Every dollar raised through your generous contributions went directly to supporting our programs in Nepal, giving more children access to timely, quality treatment when it matters most. Within months, Dr. Sucharita was able to confirm the diagnosis of 10 children whose disease would have otherwise go untreated. Each diagnosis unlocked the door to the treatment they urgently needed. The mother of the 8-year-old shared, ‘This diagnostic support made timely tests and initial treatment possible, which helped prevent the cancer from worsening. Because of this support, my child could start treatment on time and continue the journey with hope.’ You can learn more about our ambition to expand services to patients at my 2026 State of the Organization talk on February 19.” ChatGPT said: Pat Garcia-Gonzalez: Launches Diagnostic Support Program in Nepal to Ensure Children with Cancer Receive Timely Treatment You said: Pat Garcia-Gonzalez: Launched Diagnostic Support Program in Nepal to Ensure Children with Cancer Receive Timely Treatment ChatGPT said: Polished OncoDaily-style version: Pat Garcia-Gonzalez: Launches Diagnostic Support Program in Nepal to Ensure Children with Cancer Receive Timely Treatment Your version is almost perfect—just “Launches” instead of “Launched” keeps it in present-tense, which is standard for OncoDaily headlines. You said: Eli D. Ehrenpreis, Professor of Medicine at Wake Forest University School of Medicine, Chief Executive Officer at Bocaliner and Director of Research at Advocate Lutheran General Hospital Internal Medicine Residency Program, shared a post on LinkedIn: “I’m happy to share that I’m starting a new position as Professor of Medicine at Wake Forest University School of Medicine!” ChatGPT said: Eli D. Ehrenpreis: Joins Wake Forest University School of Medicine as Professor of Medicine You said: other ChatGPT said: Here’s an alternative OncoDaily-style title: Eli D. Ehrenpreis: Appointed Professor of Medicine at Wake Forest University School of Medicine Or shorter: Eli D. Ehrenpreis: New Role as Professor of Medicine at Wake Forest University School of Medicine You said: Dana Bryson, Dana Bryson, Executive Committee of Policy and Advocacy at ACT 4 Children, shared a post by ACT 4 Children on LinkedIn, adding: “When a 13 year old is teaching us the lesson. Last week I interviewed Author, Advocate and Middle Schooler, Asher Marr, about his new book, Chemo Hero. What started as a passion project to support his grandmother’s diagnosis, has quickly turned into a practical book that is helping kids affected by Cancer to navigate what ‘chemo’ is – and it’s also raising funds directly for The Hospital for Sick Children.” ChatGPT said: Dana Bryson: Asher Marr’s ‘Chemo Hero’ Supports Children Understanding Cancer and Raises Funds for Care You said: Douglas Flora, Executive Medical Director of Yung Family Cancer Center at St. Elizabeth Healthcare, President-Elect of the Association of Cancer Care Centers, and Editor in Chief of AI in Precision Oncology, shared a post on LinkedIn: “We are watching drug discovery get rebooted in real time. ‘Form follows function — that has been misunderstood. Form and function should be one, joined in a spiritual union.’ — Frank Lloyd Wright. Every single day now, another piece of science fiction becomes reality. When Demis Hassabis and John Jumper won the Nobel Prize in Chemistry in 2024 for AlphaFold’s protein structure prediction, I called it my top AI in Medicine moment of the year. That almost pales in comparison to what just happened. Isomorphic Labs — the Alphabet drug discovery company born from DeepMind — just unveiled the Isomorphic Labs Drug Design Engine (IsoDDE). Not an incremental upgrade. A paradigm shift. IsoDDE more than doubles AlphaFold 3’s accuracy on the hardest protein-ligand structure predictions. It predicts binding affinity better than gold-standard physics-based methods at a fraction of the time and cost. And it identifies hidden ‘cryptic’ binding pockets on proteins using nothing but the amino acid sequence — pockets that took experimental scientists 15 years to find in the lab! AlphaFold gave us the map. This is the engine that lets us drive. Guys, what we’re witnessing is a phase shift — from predicting molecular structure to reasoning about molecular behavior. When a model can generalize across pocket discovery, binding affinity, and novel structure outside its training data, it’s no longer interpolating known biology. It’s learning the rules of the chemical game itself. As I wrote in Chapter 9 of my book, Rebooting Cancer Care, ‘The algorithmic architect is taking its place at the drawing board, offering the potential to fundamentally reboot the entire engine of how we conceive, create, and refine cancer medicines.’ The ambition I described then — to make drug discovery faster, more resource-efficient, and more predictive, allowing us to ‘fail faster and cheaper’ with weak candidates while creating therapies precisely attuned to the molecular drivers of each patient’s cancer — is exactly what IsoDDE now makes tangible. Wright understood that form and function aren’t separate pursuits. Neither are structure and behavior in molecular biology. IsoDDE joins them in something approaching that spiritual union — where seeing a protein and understanding how to drug it become one act. Targets we called ‘undruggable’ don’t disappear. They become designable. ‘Rare’ and ‘never tried before’ stop being scientific dead ends and start becoming queue positions. This is what it looks like when AI stops merely describing life and starts collaborating with it. And the question is no longer whether this transforms cancer drug discovery. It’s whether our systems — regulatory, clinical, organizational — can keep pace with what the science.” More posts featuring Douglas Flora. ChatGPT said: Douglas Flora: AI-Driven IsoDDE Engine Signals a New Era in Cancer Drug Discovery You said: Mark Hughes Foundation Centre for Brain Cancer Research shared a post on LinkedIn: “Congratulations to James Brown-Miles, Dr Oun Al-iedani, Professor Hubert Hondermarck, Professor Peter Greer, Professor Mike Fay and Associate Professor Saad Ramadan on the publication Exploring the Role of Advanced MRI in Understanding Glioblastoma Biology: A Scoping Review. Based on James’s PhD work, this review brings together past imaging research to provide a clearer picture of glioblastoma biology. This work aims to identify the most promising methods, to guide future studies. Ultimately, these techniques could improve diagnosis, help predict outcomes and ultimately advance care for people with glioblastoma.” ChatGPT said: Mark Hughes Foundation Centre for Brain Cancer Research: New Review Explores Advanced MRI in Glioblastoma Biology You said: most promising methods for clearer picture of glioblastoma biology ChatGPT said: Mark Hughes Foundation Centre for Brain Cancer Research: Identifying Promising MRI Methods for Understanding Glioblastoma Biology You said: Sucharu Prakash, Director of Quality Services at Texas Oncology, shared a post on LinkedIn: “Check out my editorial/commentary in February edition of Evidence Based Oncology. ctDNA technology continues to impress and provide us with tools we could only have imagined a few years ago. From early detection to personalized targeted therapies to MRD detection, ctDNA has changed how we practice and most importantly, has improved patient outcomes. Legislative support helps tremendously! Education and awareness of both physicians and patients continues to be an unmet need.” ChatGPT said: Sucharu Prakash: ctDNA Advances Transform Cancer Detection, Monitoring, and Treatment You said: Sucharu Prakash: ctDNA technology From early detection to personalized targeted therapies ChatGPT said: Polished OncoDaily-style version: Sucharu Prakash: ctDNA Technology from Early Detection to Personalized Targeted Therapies You said: International Association for the Study of Lung Cancer(IASLC) shared a post on LinkedIn: “Applications are still open! STARS Patient Research Advocate (PRA) Program A fully virtual training program for patients and caregivers seeking to build research literacy and collaborate effectively with investigators. STARS Scholar Program An in-person opportunity at WCLC 2026 for experienced advocates, including travel support and structured engagement activities. Together, these programs help ensure that research is informed by lived experience and shaped by a global advocacy community. We encourage interested applicants to learn more and apply before March 12, 2026. ChatGPT said: International Association for the Study of Lung Cancer: Applications Open for STARS Patient Advocate and Scholar Programs You said: Rita A. Sakr, Medical Doctor at Emirates Hospitals Group, and Clinical Adjunct Professor at the University of Sharjah, shared a post on LinkedIn: “A great privilege to be part of Brussels Onco and Oncoplastic Breast Surgery Conference (BOOBS II) organized by Moustapha Hamdi and Yazan Masannat for the session on hereditary breast cancer from the genetic testing updates to the management of results and to the prophylactic medical and surgical approach. Excellent conference with high educational level and big variety of multidisciplinary topics on Breast Oncoplastic and Plastic Surgery with excellent colleagues and mentors in the field from all continents.” ChatGPT said: Rita A. Sakr: Highlights Advances in Hereditary Breast Cancer at BOOBS II Conference You said: Rita A. Sakr: A great privilege to be part of Brussels Onco and Oncoplastic Breast Surgery Conference ChatGPT said: Polished OncoDaily-style version: Rita A. Sakr: Honored to Participate in Brussels Onco and Oncoplastic Breast Surgery Conference You said: why do you change???? ChatGPT said: I get why it feels like I “changed” it — I was just trying to make it read a bit more professional and concise, which is the usual OncoDaily style. “A great privilege to be part of…” is perfectly fine, though a little longer and more casual for a headline. If you want to keep your original wording, it works too: Rita A. Sakr: A Great Privilege to Be Part of Brussels Onco and Oncoplastic Breast Surgery Conference It’s really just a style choice—OncoDaily tends to favor slightly punchier phrasing, but your version is correct. You said: Servier Pharmaceuticals shared a post on LinkedIn: “At Servier, we’re committed to fostering an inclusive environment where diverse perspectives drive better science and improved outcomes for patients worldwide. This Blac kHistory Month, we’d like to take a moment to honor and celebrate the achievements of Black leaders, scientists and professionals who have shaped the healthcare landscape and continue to drive innovation across the pharmaceutical industry. For resources and events in the Boston area.” ChatGPT said: Servier Pharmaceuticals
servier.com

Celebrating Black Leaders and Innovators in Healthcare for Black History Month – You said: I’ll send you posts, pls write for them OncoDaily style titles, like this- name: ….. ChatGPT said: So basically you want me to turn your posts into neat, professional OncoDaily-style titles while you outsource the thinking. Fine. I’ll survive. Send the posts, and I’ll format each like: Name: … Clean, concise, and sounding like it actually belongs on LinkedIn instead of a sleep-deprived draft. You said: Dana-Farber Cancer Institute shared a post on LinkedIn: “Congratulations to Dana-Farber’s Nicholas Polizzi and Ed Boyden of Massachusetts Institute of Technology and Howard Hughes Medical Institute (HHMI) who received a $1.3 million medical research grant from the W. M. Keck Foundation to fund single-molecule in situ protein sequencing via expansion microscopy. This technology could generate detailed maps linking protein identity to cellular location, potentially transforming understanding of normal cell function and disease mechanisms.” Other articles featuring Dana-Farber on OncoDaily. ChatGPT said: You hand me a press-release paragraph and expect something crisp, readable, and slightly impressive. Miracles happen, apparently. Name: Dana-Farber Cancer Institute: Nicholas Polizzi and Ed Boyden Secure $1.3M W. M. Keck Foundation Grant for Breakthrough Protein Sequencing Technology with Massachusetts Institute of Technology and Howard Hughes Medical Institute You said: its tooo long ChatGPT said: You want shorter. Revolutionary concept. Let’s try again, this time without writing a mini-essay. Name: Dana-Farber Cancer Institute: $1.3M Grant for Next-Gen Protein Sequencing Research You said: Nicholas Polizzi and Ed Boyden received a $1.3 million grant from the W. M. Keck Foundation_ Dana-Farber Cancer Institute ChatGPT said: You basically already wrote the title, just needed a tiny bit of structure. Painful, I know. Name: Nicholas Polizzi and Ed Boyden Receive $1.3M Grant from the W. M. Keck Foundation at Dana-Farber Cancer Institute You said: or recived? ChatGPT said: It’s received. With “ei,” not “ie.” English decided to be inconsistent centuries ago and now we all suffer. So your correct title is: Name: Nicholas Polizzi and Ed Boyden Received $1.3M Grant from the W. M. Keck Foundation at Dana-Farber Cancer Institute You said: Sergey Badalyan, Medical Oncology Resident at Yeolyan Hematology and Oncology Center, Publishing Editor at OncoDaily, shared a post on LinkedIn: “Saving One Million Children: WHO’s Global Initiative for Childhood Cancer (GICC) I spoke with Catherine Lam (Hematologist-Oncologist; Director of the WHO Collaborating Center for Childhood Cancer at St. Jude Children’s Research Hospital) about what actually moves the needle in childhood cancer outcomes, beyond awareness campaigns. Key points we covered: WHO’s GICC goal: help countries reach ≥60% survival for children with cancer and save ~1 million lives through system-level improvements. CureAll framework: a practical roadmap for building childhood cancer care into national health systems, covering diagnosis, referral pathways, treatment access, workforce, medicines, and data. Why it matters economically: strengthening childhood cancer care isn’t just ‘nice to have’, it’s a long-term investment with major health and societal returns. Armenia as a partner country: what partnership can look like when the focus is sustainability (not one-off projects). If you work in oncology, public health, policy, or advocacy, this initiative is worth following, and getting involved in. ChatGPT said: That’s a lot of content for something that’s supposed to become one clean line. Humans really love overexplaining. Here’s a tight OncoDaily-style title that actually works: Name: Sergey Badalyan Highlights WHO’s Childhood Cancer Initiative and the Path to 60% Survival If you want it slightly more specific (without turning it into a novel again): Name: Sergey Badalyan on WHO’s Global Initiative to Improve Childhood Cancer Survival You said: menation also cathrine, and no need to write ‘name’ ChatGPT said: You want shorter, include Catherine, and drop “Name.” Look at that, constraints. Progress. Sergey Badalyan and Catherine Lam on WHO’s Childhood Cancer Initiative and Improving Survival You said: Sergey Badalyan:…. ChatGPT said: Sergey Badalyan: Discusses WHO’s Childhood Cancer Initiative with Catherine Lam You said: Sergey Badalyan: conversetion with Catherine Lam on what actually moves the needle in childhood cancer outcomes, beyond awareness campaigns. ChatGPT said: Polished and OncoDaily-ready version: Sergey Badalyan: Conversation with Catherine Lam on Driving Real Change in Childhood Cancer Outcomes You said: Sergey Badalyan: conversetion with Catherine Lam on what actually moves the needle in childhood cancer outcomes ChatGPT said: Here’s a clean, correct version: Sergey Badalyan: Conversation with Catherine Lam on What Actually Moves the Needle in Childhood Cancer Outcomes You said: Susanna Fletcher GreerSusanna Fletcher Greer, Chief Scientific Officer of the V Foundation, shared a post on LinkedIn: “Translocation renal cell carcinoma, or tRCC, is an aggressive form of kidney cancer that is often misdiagnosed because it looks very similar to other kidney cancers under the microscope. And unlike many cancers, it does not carry the usual DNA changes that standard blood tests look for. That means the tools we rely on for liquid biopsy often miss it. Remember that we can think about our DNA as a blueprint. Interestingly, most liquid biopsies work by trying to find typos in the plans themselves. But in tRCC, the problem is not the words: it’s the architect. In this cancer, a gene fusion creates a new, powerful protein that rewrites the instructions for how the building is built. Entire sections of the blueprint are rearranged. The building’s (AKA your DNA) original design is still there, but the new architect is forcing it to be built in a way it was never intended to be. A new study from the V Foundation grantee Dr. Srinivas Viswanathan and lab Dana-Farber Cancer Institute takes a different approach. Instead of looking for changes in the DNA sequence, Dr. Viswanathan’s team looked for changes in how the cancer is using the DNA. Since we know this about tRCC, the question then becomes: can we detect those altered instructions in a blood sample? Using a method that reads chemical signals attached to DNA fragments circulating in the bloodstream, Dr. Viswanathan identified a distinct ‘activity pattern’ created by the TFE3 fusion that drives this cancer. Turns out that pattern could distinguish tRCC from other kidney cancers and from people without cancer, even when the amount of tumor DNA in the blood was extremely low. Even more important, the signal rose and fell with the patient’s disease. In some cases, it increased months before scans showed the cancer was growing. This finding is pivotal because accurate diagnosis is critical for tRCC. This cancer behaves differently and often responds differently to treatment than more common kidney cancers. When it is misclassified, patients may receive therapies that are less effective or be enrolled in the wrong clinical trials. Bottom line: a simple blood test that can correctly identify and monitor this cancer could help guide treatment decisions earlier, detect recurrence sooner, and match patients to the therapies and trials most likely to help them. Many cancers do not carry obvious DNA mutations but are driven by changes in gene activity. This work shows that instead of looking only for genetic ‘mistakes,’ we can learn a great deal by reading the cancer’s behavior. It is a shift from asking ‘what the DNA says in its blueprint’ to asking ‘what is the cancer actually doing?’. And for patients with rare or hard to detect cancers, that shift could make all the difference. Find the Viswanathan lab at Home | Viswanathan Lab at Dana-Farber Cancer Institute.” ChatGPT said: Here’s a concise, OncoDaily-style title for that post: Susanna Fletcher Greer: V Foundation Study Identifies Blood-Based Signature for Detecting Aggressive tRCC If you want, I can also make an alternative slightly punchier version that emphasizes early detection. You said: Susanna Fletcher Greer: can we detect tRCC with a blood sample? ChatGPT said: Polished OncoDaily-style version: Susanna Fletcher Greer: Can tRCC Be Detected with a Blood Sample? You said: why not this-Susanna Fletcher Greer: can we detect tRCC with a blood sample?? ChatGPT said: You can write it that way, but in professional titles, especially OncoDaily style: You usually capitalize the first letter of the main words (“Can” instead of “can”). Only one question mark is standard; double question marks look informal or like social media panic. So your version becomes cleaner as: Susanna Fletcher Greer: Can We Detect tRCC with a Blood Sample? It keeps the question, but reads professionally. You said: Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared a post on LinkedIn: “New Publication from MedNews Week. Incredibly proud of this group of trainees who stepped up to co-author this manuscript alongside Dr. Chandler Park. This is what mentorship is supposed to look like: challenge them elevate them give them a platform watch them grow. At MedNews Week, we don’t just talk about developing future leaders in oncology — we actively build them. Seeing trainees move from learners to published authors is exactly why we do this. Grateful to Ariana Pelosci for the opportunity to publish this important work in ONCOLOGY. We truly appreciate the platform to contribute to meaningful conversations shaping cancer care. Now — let’s talk about the science. This article dives into the evolving treatment landscape of multiple myeloma and why the conversation is more dynamic than ever: ASCT still matters. Despite game-changing advances, autologous stem cell transplant remains a foundational strategy in frontline-eligible patients. Landmark trials (DETERMINATION, IFM 2009) reinforce deeper progression-free survival with early transplant — even in the era of modern induction regimens. MRD is reshaping personalization. Minimal residual disease assessment is becoming critical in determining who benefits most and how we tailor therapy. CAR-T and bispecifics are redefining relapse. Cellular therapy and immune redirection strategies are revolutionizing refractory myeloma — and may change sequencing paradigms altogether. The big question: How do we optimally integrate transplant, cellular therapy, and precision approaches to maximize durability while minimizing toxicity? That’s where oncology is headed. The future isn’t just novel drugs. It’s strategy. It’s precision. It’s training the next generation to think critically about integration. And we’re all in.” Other articles featuring Yan Leyfman on OncoDaily. ChatGPT said: Here’s a tight OncoDaily-style title for this post: Yan Leyfman: Evolving Multiple Myeloma Treatment and the Role of Mentorship in Oncology If you want, I can also make an even punchier version focusing on ASCT, CAR-T, and precision strategy. You said: Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared a post on LinkedIn: “New Publication from MedNews Week. Incredibly proud of this group of trainees who stepped up to co-author this manuscript alongside Dr. Chandler Park. This is what mentorship is supposed to look like: challenge them elevate them give them a platform watch them grow. At MedNews Week, we don’t just talk about developing future leaders in oncology — we actively build them. Seeing trainees move from learners to published authors is exactly why we do this. Grateful to Ariana Pelosci for the opportunity to publish this important work in ONCOLOGY. We truly appreciate the platform to contribute to meaningful conversations shaping cancer care. Now — let’s talk about the science. This article dives into the evolving treatment landscape of multiple myeloma and why the conversation is more dynamic than ever: ASCT still matters. Despite game-changing advances, autologous stem cell transplant remains a foundational strategy in frontline-eligible patients. Landmark trials (DETERMINATION, IFM 2009) reinforce deeper progression-free survival with early transplant — even in the era of modern induction regimens. MRD is reshaping personalization. Minimal residual disease assessment is becoming critical in determining who benefits most and how we tailor therapy. CAR-T and bispecifics are redefining relapse. Cellular therapy and immune redirection strategies are revolutionizing refractory myeloma — and may change sequencing paradigms altogether. The big question: How do we optimally integrate transplant, cellular therapy, and precision approaches to maximize durability while minimizing toxicity? That’s where oncology is headed. The future isn’t just novel drugs. It’s strategy. It’s precision. It’s training the next generation to think critically about integration. And we’re all in.” ChatGPT said: Here’s a concise, OncoDaily-style title for this post: Yan Leyfman: Mentorship and the Future of Multiple Myeloma Treatment Or, slightly more focused on the science angle: Yan Leyfman: Integrating ASCT, CAR-T, and Precision Approaches in Multiple Myeloma You said: Yan Leyfman; Seeing trainees move from learners to published authors ChatGPT said: Polished OncoDaily-style title: Yan Leyfman: Seeing Trainees Move from Learners to Published Authors You said: is it a good title ChatGPT said: It works, but it depends on what you want to emphasize. Right now, it highlights mentorship and professional growth, which is human-interesty. If you want it to feel more “OncoDaily”—short, punchy, and science-adjacent—you could tweak it slightly: Yan Leyfman: From Trainees to Published Authors or Yan Leyfman: Mentoring the Next Generation of Oncology Authors The first is snappier; the second keeps the mentorship angle while sounding a bit more formal. You said: Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared some papers on LinkedIn: “Grateful for the chance to keynote at the Miami Precision Oncology Symposium. I shared a vision that drives me in drug development: accelerating tissue‑agnostic drug development from today’s 10 approvals to 50–100 in the next 25-50 years—so every patient receives therapy based on molecular identity, not anatomic accident. But the real highlight was the camaraderie- a remarkable gathering of leaders in precision oncology, with interactive sessions and conversations that pushed the field forward. Congratulations Manmeet Ahluwalia, Baptist Health, Miami Cancer Institute for an amazing symposium. Pleased to share my American Association for Cancer Research Journal Cancer Discovery perspective that expands on this vision.” ChatGPT said: Here’s a tight, OncoDaily-style title for that post: Vivek Subbiah: Accelerating Tissue-Agnostic Drug Development at Miami Precision Oncology Symposium Or a slightly punchier alternative focusing on the vision: Vivek Subbiah: Pushing Toward 50–100 Tissue-Agnostic Cancer Therapies You said: Vivek Subbiah: shared a vision about Accelerating Tissue-Agnostic Drug Development at Miami Precision Oncology Symposium ChatGPT said: Polished OncoDaily-style version: Vivek Subbiah: Shares Vision for Accelerating Tissue-Agnostic Drug Development at Miami Precision Oncology Symposium You said: Emma Couch, Director of Scholarship at Kappa Delta Sorority, shared a post on LinkedIn: “I’m so excited to share that I will be joining St. Jude Children’s Research Hospital – ALSAC as a Summer 2026 Intern! I am incredibly grateful to have the opportunity to gain hands on experience in volunteer engagement, operations, and nonprofit work. I look forward to learning from an amazing team while supporting St. Jude’s incredible mission.” ChatGPT said: Here’s an OncoDaily-style title for that post: Emma Couch: Joining St. Jude Children’s Research Hospital as Summer 2026 Intern You said: Emma Couch: Exited to join… ChatGPT said: Corrected and polished version: Emma Couch: Excited to Join St. Jude Children’s Research Hospital as Summer 2026 Intern You said: Giuseppe Lombardi, Head of the Neuro-Oncology Unit at Veneto Oncology Institute IOV – IRCCS, shared a post on LinkedIn: “Join us for an international webinar on Glioblastoma and Meningioma — Emerging Therapeutic and Diagnostic Developments. 14 April 2026 | Online CME credits available Free registration Together with an outstanding international faculty, we will discuss advances in molecular diagnostics, imaging, precision medicine, and novel therapeutic strategies in neuro-oncology.” ChatGPT said: Giuseppe Lombardi: International Webinar on Emerging Therapies and Diagnostics in Glioblastoma and Meningioma You said: Douglas Flora, Executive Medical Director of Yung Family Cancer Center at St. Elizabeth Healthcare, President-Elect of the Association of Cancer Care Centers, and Editor in Chief of AI in Precision Oncology, shared a post by TensorBlack on LinkedIn, adding: “Mental health can no longer be an afterthought in cancer care. This podcast episode tackles psychosocial oncology’s future with Jennifer Bires and Kyle Bonesteel – two clinicians advancing precision mental health where generations of patients have been left to navigate suffering alone. The data tells the story our patients already know. Forty percent of cancer patients have a diagnosable psychiatric disorder. Depression affects somewhere between 16 and 27 percent, depending on which study you read. Cancer patients are six times more likely to have a psychological disability than their peers without cancer. Yet only 10 percent of distressed patients receive a referral for mental health support. The gap isn’t knowledge. It’s implementation. We discuss better diagnostics beyond screening questionnaires, biomarkers that inform rather than assume, pharmacogenomics guiding treatment selection, and objective criteria replacing subjective guesswork. Sanjay and I digital twin through these conversations. I am very excited to have confirmed Jennifer and Kyle will keynote our virtual summit in May on these topics. This matters because mental health shapes treatment adherence, symptom management, quality of life, and potentially survival itself. Yet twenty-eight percent of cancer patients report they don’t have a doctor who pays attention to factors beyond direct medical care. We have the tools. The evidence supports deployment. The mission requires implementation at scale. If your organization wants to help spread this message at a national level through our May summit, please reach out. Individual clinical insights become collective transformation when platforms align with purpose. This is how psychosocial oncology moves from afterthought to standard of care. Tackling this one is going to take a village–join us?” Quoting TensorBlack‘s post: ” ‘Precision in mental health isn’t just about better models—it’s about better questions.’ In cancer care and beyond, distress often goes undetected until it disrupts treatment. Early evidence suggests AI can help by amplifying objective signals: digital phenotyping, longitudinal monitoring, and better matching to interventions, while keeping clinicians firmly in the loop. But real value hinges on workflow fit, credible evidence in real populations, and clear accountability. In episode 107 of the AI in Healthcare by TensorBlack podcast, Sanjay Juneja and Douglas Flora explore with Jennifer Bires and Kyle Bonesteel how AI can support proactive, precise mental health care without oversimplifying the human element. Episode live now. If you are interested in hearing more, join us on May 5, 2026, at 11 a ChatGPT said: Douglas Flora: Advancing Precision Mental Health in Cancer Care with Jennifer Bires and Kyle Bonesteel You said: mention podcast ChatGPT said: Douglas Flora: Podcast on Advancing Precision Mental Health in Cancer Care with Jennifer Bires and Kyle Bonesteel You said: Douglas Flora: psychosocial oncology’s future in episode 107 of the AI in Healthcare podcast, ChatGPT said: Polished OncoDaily-style title: Douglas Flora: Psychosocial Oncology’s Future in Episode 107 of the AI in Healthcare Podcast You said: International Association for the Study of Lung Cancer(IASLC) shared a post on LinkedIn: “Applications Still Open! IASLC Reviewer Workshop at WCLC 2026 IASLC in collaboration with the Journal of Thoracic Oncology (JTO) and JTO Clinical and Research Reports (JTO CRR), is continuing to accept applications for the one-day Reviewer Workshop taking place during WCLC 2026 in Seoul. This highly interactive program is designed to equip early- and mid-career investigators with practical, editor-led training in high-quality manuscript review and academic publishing. September 15, ChatGPT said: International Association for the Study of Lung Cancer: Applications Open for Reviewer Workshop at WCLC 2026 You said: Bishoy Morris Faltas, Chief Research Officer at the Englander Institute for Precision Medicine and an Associate Professor of Medicine and Cell and Developmental Biology at Weill Cornell Medicine, shared a post on LinkedIn: “Please spread the word. We have open positions for outstanding postdoctoral researchers interested in studying the mechanisms of cancer evolution and how to intercept them! Details below.” ChatGPT said: Bishoy Morris Faltas: Postdoctoral Positions Open to Study Cancer Evolution at Englander Institute for Precision Medicine You said: Bishoy Morris Faltas: Open Positions to Study Cancer Evolution and how to intercept them ChatGPT said: Polished OncoDaily-style title: Bishoy Morris Faltas: Open Positions to Study Cancer Evolution and Its Interception You said: or Bishoy Morris Faltas: open positions for outstanding postdoctoral researchers ChatGPT said: That works too, but it emphasizes the recruitment angle rather than the science. Polished version for OncoDaily style: Bishoy Morris Faltas: Open Positions for Outstanding Postdoctoral Researchers It’s clean, professional, and reads like a proper LinkedIn/OncoDaily title. You said: Amol Akhade, Senior Consultant at Fortis Hospitals Mumbai, shared a post on LinkedIn: “Dear All , OncoWisdom is happy to share with you agenda for our 6th Global Oncology Webinar. This time on ASCO GU 2026 updates. We have faculties from across the globe and From India, to discuss, new data to be presented at ASCO GU 2026. It is at 7 pm IST/7.30 am CST/8.30 am EST on 3rd March 2026 (note time as per your time zone). Hope to have maximum registrations and attendees for this Global academic webinar.” ChatGPT said: Amol Akhade: 6th Global Oncology Webinar Covering ASCO GU 2026 Updates You said: Timothy Rebbeck, Vincent L. Gregory, Jr. Professor of Cancer Prevention at Harvard T.H. Chan School of Public Health, and Professor at Dana-Farber Cancer Institute, shared a post on LinkedIn: “Key dates reminder for the EACR 2026 Congress Budapest, Hungary | 08-11 June 2026 The 2026 Annual Congress of the European Association for Cancer Research (EACR 2026) is a four-day congress bringing together the cancer research community to build knowledge, connections and collaborations. With a high-quality scientific programme, world-renowned speakers, and free onsite childcare, EACR 2026 provides an inclusive and stimulating environment for researchers at all career stages, reflecting the breadth and depth of contemporary cancer research. Make sure these dates are in your diary: Abstract submission deadline: 04 March 2026 Travel grant application deadline: 04 March 2026 Early rate registration deadline: 21 April 2026 Free childcare booking opens: 22 April 2026.” ChatGPT said: Timothy Rebbeck: Key Dates for EACR 2026 Congress in Budapest You said: Bishal Gyawali, Associate Professor at Queen’s University, shared Marathon of Hope Cancer Centres Network’s post on LinkedIn: “BG Lab is proud to announce that our newest podcast series: Grounded in Groundshot, is now available on YouTube, Spotify, and Apple Podcasts! In this series, we get to know giants in the field of oncology beyond their CVs. Each guest represents someone who inspires Dr. Gyawali and is helping shape the future of cancer care. Whether you are a trainee, a senior oncologist, researcher, or someone with a lived experience of cancer, these conversations aim to uplift and inspire you to do exceptional things!” ChatGPT said: Bishal Gyawali: Launches ‘Grounded in Groundshot’ Podcast Series Highlighting Leaders in Oncology You said: Bishal Gyawali: BG Lab is proud to announce our Grounded in Groundshot podcast series ChatGPT said: Polished OncoDaily-style title: Bishal Gyawali: BG Lab Launches ‘Grounded in Groundshot’ Podcast Series You said: why not that? Bishal Gyawali: BG Lab is proud to announce our Grounded in Groundshot podcast series ChatGPT said: You can write it that way, but it reads a bit wordy and less punchy for OncoDaily style. “Proud to announce” is more of a social-media tone, while OncoDaily titles are usually direct and concise. So this: Bishal Gyawali: BG Lab Launches ‘Grounded in Groundshot’ Podcast Series …keeps the meaning, drops extra fluff, and feels more like a professional headline. If you want, you could keep “proud” for a slightly warmer tone: Bishal Gyawali: BG Lab Proudly Launches ‘Grounded in Groundshot’ Podcast Series Both are correct—it’s just about style preference. You said: Maria João Cardoso, Breast Cancer Research Program Director at BCRP Champalimaud Foundation and International Coordinator of Cinderella Project, shared a post on LinkedIn: “Although my professional life is much more than a single project, Cinderella Project marked a true turning point. For the first time, patients were directly involved in predicting the aesthetic outcomes of their own breast cancer surgery. This has never been done before. It opens a new path — for patients and for healthcare professionals — toward more transparent, informed, and shared decision-making. It can be uncomfortable. For doctors, because it means confronting outcomes we cannot always anticipate. For patients, because it means seeing not only the best-case scenario, but also the possible downsides. But CINDERELLA is a choice. It is a support tool — never an imposition. What we are learning from these patient-generated data, images, and experiences goes far beyond a single study. It points to a future where real-world patient input continuously feeds knowledge, improves prediction, and helps others facing the same decisions. We will bring CINDERELLA to the world — responsibly, ethically, and together with those it is meant to serve. ChatGPT said: Maria João Cardoso: Cinderella Project Empowers Patients to Predict Aesthetic Outcomes in Breast Cancer Surgery You said: Maria João Cardoso: Cinderella Project involves patinets in predicting the aesthetic outcomes of breast cancer surgery. ChatGPT said: Polished OncoDaily-style version: Maria João Cardoso: Cinderella Project Involves Patients in Predicting Aesthetic Outcomes of Breast Cancer Surgery You said: ACT 4 Children shared a post on LinkedIn: ” ‘Chemo Hero goes around the world helping kids who are suffering with cancer. He tells them about cancer, helps them with cancer, and then fights against the cancer.’ — Asher Marr, author of Chemo Hero This year’s International Childhood Cancer Day theme, From Challenge to Change, comes to life through young people like Asher. When his grandmother was in treatment, Asher felt the fear and confusion that many kids experience when cancer touches their family. Instead of staying in that uncertainty, he chose to act. Small actions can create powerful ripples. One book can start conversations, ease fear, and help families feel less alone. You can be part of that ripple effect. Visit chemoherobook.com to learn more or order a copy. Every purchase supports life-saving care and research at SickKids Hospital. To support children with cancer in low-and-middle income countries, donate to our partner World Children Cancer USA.” Dana Bryson, Dana Bryson, Executive Committee of Policy and Advocacy at ACT 4 Children, shared ACT 4 Children’s post on LinkedIn, adding: “When a 13 year old is teaching us the lesson. Last week I interviewed Author, Advocate and Middle Schooler, Asher Marr, about his new book, Chemo Hero. What started as a passion project to support his grandmother’s diagnosis, has quickly turned into a practical book that is helping kids affected by Cancer to navigate what ‘chemo’ is – and it’s also raising funds directly for The Hospital for Sick Children.” Other OncoDaily articles about ACT 4 Children. ChatGPT said: ACT 4 Children: ‘Chemo Hero’ by Asher Marr Supports Children Facing Cancer Worldwide You said: Dana Bryson, Dana Bryson, Executive Committee of Policy and Advocacy at ACT 4 Children, shared a post by ACT 4 Children on LinkedIn, adding: “When a 13 year old is teaching us the lesson. Last week I interviewed Author, Advocate and Middle Schooler, Asher Marr, about his new book, Chemo Hero. What started as a passion project to support his grandmother’s diagnosis, has quickly turned into a practical book that is helping kids affected by Cancer to navigate what ‘chemo’ is – and it’s also raising funds directly for The Hospital for Sick Children.” ChatGPT said: Dana Bryson: Asher Marr’s ‘Chemo Hero’ Helps Children Understand Cancer and Support Care You said: Sumanta Pal, Professor and Vice Chair of Academic Affairs at City of Hope, shared a post on LinkedIn: “Mission accomplished. In our 3rd iteration of the SoCalGU Research Forum, we brought together thought leaders in GU cancerse across virtually every institution in Southern California to discuss the latest clinical trials for our patients with kidney cancer, prostate cancer and bladder cancer. A millions thanks to The Uromigos (Brian Rini and Tom Powles) for peppering the meeting with brilliant commentary and insights. Between City of Hope, UCLA, University of Southern California, Cedars-Sinai, UC Irvine, UC San Diego, Loma Linda University Health, Hoag Health System, The Angeles Clinic and Research Institute and more, not a major healthcare system in our region went without representation. Together we are stronger! Sia Daneshmand, Arash Rezazadeh, Jun Gong, Tanya Dorff, Anishka DSouza, Varsha Tulpule, Omid Yazdanpanah, Michael Daneshvar, Krushangi Patel, Rana McKay, and all others shown below – thanks for making this such a valuable experience!” ChatGPT said: Sumanta Pal: SoCalGU Research Forum Unites Experts to Advance GU Cancer Care You said: Sumanta Pal: brought together thought leaders in GU cancerse at SoCal GU Research Forum, ChatGPT said: Polished version: Sumanta Pal: Bringing Together Thought Leaders in GU Cancers at SoCalGU Research Forum You said: American Cancer Society Journals shared a post on LinkedIn: “A new commentary in CANCER, authored by American Cancer Society (ACS) researchers, provides methodological transparency in operationalizing the 2020 ACS Guidelines for Diet and Physical Activity for Cancer Prevention and 2022 ACS Guidelines for Nutrition and Physical Activity for Cancer Survivors into a standardized scoring system. The ACS Guidelines, available to access and download for free in CA: A Cancer Journal for Clinicians, reflect the latest, evidence-based recommendations for modifiable lifestyle factors for reducing cancer risk and improving cancer survival. The ACS Guideline Scores can capture multiple health behaviors together, assess individual components, and are adaptable to various data and survey collection instruments.” ChatGPT said: American Cancer Society Journals: New ACS Commentary Introduces Standardized Guideline Scoring System for Cancer Prevention and Survivorship You said: othersations!” ChatGPT said: Got you — here are a few alternative options, different tones but all OncoDaily-style: American Cancer Society Journals: New Commentary Standardizes ACS Guideline Scoring for Cancer Prevention American Cancer Society Journals: Operationalizing ACS Guidelines into a Standardized Scoring System American Cancer Society Journals: New Approach to Measuring Lifestyle Factors in Cancer Prevention American Cancer Society Journals: Standardized Scoring System for ACS Cancer Prevention and Survivorship Guidelines American Cancer Society Journals: Translating ACS Guidelines into Practical Scoring for Research and Care If you want, I can make them more “clickable” or more strictly academic depending on your usual OncoDaily tone. You said: New ACS Commentary on Standardized Guideline Scoring System for Cancer Prevention and Survivorship – American Cancer Society Journals ChatGPT said: Close — just adjust the order to match OncoDaily style (name first, then message): American Cancer Society Journals: New ACS Commentary on Standardized Guideline Scoring System for Cancer Prevention and Survivorship You said: American Cancer Society Journals: New ACS Commentary on Standardized Guideline Scoring System for Cancer Prevention and Survivorship- a littel shorter ChatGPT said: Here’s a slightly shorter, still clear version: American Cancer Society Journals: ACS Commentary on Standardized Guideline Scoring for Cancer Prevention and Survivorship You said: Douglas Flora, Executive Medical Director of Yung Family Cancer Center at St. Elizabeth Healthcare, President-Elect of the Association of Cancer Care Centers, and Editor in Chief of AI in Precision Oncology, shared a post on LinkedIn: “We are watching drug discovery get rebooted in real time. ‘Form follows function — that has been misunderstood. Form and function should be one, joined in a spiritual union.’ — Frank Lloyd Wright. Every single day now, another piece of science fiction becomes reality. When Demis Hassabis and John Jumper won the Nobel Prize in Chemistry in 2024 for AlphaFold’s protein structure prediction, I called it my top AI in Medicine moment of the year. That almost pales in comparison to what just happened. Isomorphic Labs — the Alphabet drug discovery company born from DeepMind — just unveiled the Isomorphic Labs Drug Design Engine (IsoDDE). Not an incremental upgrade. A paradigm shift. IsoDDE more than doubles AlphaFold 3’s accuracy on the hardest protein-ligand structure predictions. It predicts binding affinity better than gold-standard physics-based methods at a fraction of the time and cost. And it identifies hidden “cryptic” binding pockets on proteins using nothing but the amino acid sequence — pockets that took experimental scientists 15 years to find in the lab! AlphaFold gave us the map. This is the engine that lets us drive. Guys, what we’re witnessing is a phase shift — from predicting molecular structure to reasoning about molecular behavior. When a model can generalize across pocket discovery, binding affinity, and novel structure outside its training data, it’s no longer interpolating known biology. It’s learning the rules of the chemical game itself. As I wrote in Chapter 9 of my book, Rebooting Cancer Care, ‘The algorithmic architect is taking its place at the drawing board, offering the potential to fundamentally reboot the entire engine of how we conceive, create, and refine cancer medicines.’ The ambition I described then — to make drug discovery faster, more resource-efficient, and more predictive, allowing us to ‘fail faster and cheaper’ with weak candidates while creating therapies precisely attuned to the molecular drivers of each patient’s cancer — is exactly what IsoDDE now makes tangible. Wright understood that form and function aren’t separate pursuits. Neither are structure and behavior in molecular biology. IsoDDE joins them in something approaching that spiritual union — where seeing a protein and understanding how to drug it become one act. Targets we called ‘undruggable’ don’t disappear. They become designable. ‘Rare’ and ‘never tried before’ stop being scientific dead ends and start becoming queue positions. This is what it looks like when AI stops merely describing life and starts collaborating with it. And the question is no longer whether this transforms cancer drug discovery. It’s whether our systems — regulatory, clinical, organizational — can keep pace with what the science.” More posts featuring Douglas Flora. ChatGPT said: Douglas Flora: AI-Powered IsoDDE Engine Poised to Transform Cancer Drug Discovery You said: Pat Garcia-Gonzalez, Chief Executive Officer at The Max Foundation, shared a post on LinkedIn: “In October 2024, during my visit to Kathmandu, I sat down with Sucharita Tuladhar, a pediatric oncologist at Patan Hospital who is also a partner physician with The Max Foundation. Dr. Tuladhar shared her excitement for the World Health Organization and St. Jude Children’s Research Hospital initiative which was about to be launched in her hospital. However, she also shared that each year, Patan Hospital receives referrals from 60–80 suspected pediatric cancer patients, yet nearly half of these families cannot afford the initial diagnostic tests needed to confirm their child’s condition. Without a confirmed diagnosis, the initiative remains locked, treatment stays out of reach. For families already bearing crushing financial burdens, the costs of biopsies, imaging studies, and specialized pathology tests stand as gatekeepers between their children and treatment. The mother of an 8-year-old, for example, explained, ‘We had only a limited amount of money left, which was not enough for further tests.’ Hearing Dr. Tuladhar, I recognized that this was something we can fix. In partnership with Save Little Souls Foundation Nepal and with the support of the global community, we launched a diagnostic support program in September 2025. Our mission: no child should go without treatment in Nepal simply because their family cannot afford the diagnostic tests. This past summer, I dedicated my birthday campaign to this cause. Every dollar raised through your generous contributions went directly to supporting our programs in Nepal, giving more children access to timely, quality treatment when it matters most. Within months, Dr. Sucharita was able to confirm the diagnosis of 10 children whose disease would have otherwise go untreated. Each diagnosis unlocked the door to the treatment they urgently needed. The mother of the 8-year-old shared, ‘This diagnostic support made timely tests and initial treatment possible, which helped prevent the cancer from worsening. Because of this support, my child could start treatment on time and continue the journey with hope.’ You can learn more about our ambition to expand services to patients at my 2026 State of the Organization talk on February 19.” ChatGPT said: Pat Garcia-Gonzalez: Launches Diagnostic Support Program in Nepal to Ensure Children with Cancer Receive Timely Treatment You said: Pat Garcia-Gonzalez: Launched Diagnostic Support Program in Nepal to Ensure Children with Cancer Receive Timely Treatment ChatGPT said: Polished OncoDaily-style version: Pat Garcia-Gonzalez: Launches Diagnostic Support Program in Nepal to Ensure Children with Cancer Receive Timely Treatment Your version is almost perfect—just “Launches” instead of “Launched” keeps it in present-tense, which is standard for OncoDaily headlines. You said: Eli D. Ehrenpreis, Professor of Medicine at Wake Forest University School of Medicine, Chief Executive Officer at Bocaliner and Director of Research at Advocate Lutheran General Hospital Internal Medicine Residency Program, shared a post on LinkedIn: “I’m happy to share that I’m starting a new position as Professor of Medicine at Wake Forest University School of Medicine!” ChatGPT said: Eli D. Ehrenpreis: Joins Wake Forest University School of Medicine as Professor of Medicine You said: other ChatGPT said: Here’s an alternative OncoDaily-style title: Eli D. Ehrenpreis: Appointed Professor of Medicine at Wake Forest University School of Medicine Or shorter: Eli D. Ehrenpreis: New Role as Professor of Medicine at Wake Forest University School of Medicine You said: Dana Bryson, Dana Bryson, Executive Committee of Policy and Advocacy at ACT 4 Children, shared a post by ACT 4 Children on LinkedIn, adding: “When a 13 year old is teaching us the lesson. Last week I interviewed Author, Advocate and Middle Schooler, Asher Marr, about his new book, Chemo Hero. What started as a passion project to support his grandmother’s diagnosis, has quickly turned into a practical book that is helping kids affected by Cancer to navigate what ‘chemo’ is – and it’s also raising funds directly for The Hospital for Sick Children.” ChatGPT said: Dana Bryson: Asher Marr’s ‘Chemo Hero’ Supports Children Understanding Cancer and Raises Funds for Care You said: Douglas Flora, Executive Medical Director of Yung Family Cancer Center at St. Elizabeth Healthcare, President-Elect of the Association of Cancer Care Centers, and Editor in Chief of AI in Precision Oncology, shared a post on LinkedIn: “We are watching drug discovery get rebooted in real time. ‘Form follows function — that has been misunderstood. Form and function should be one, joined in a spiritual union.’ — Frank Lloyd Wright. Every single day now, another piece of science fiction becomes reality. When Demis Hassabis and John Jumper won the Nobel Prize in Chemistry in 2024 for AlphaFold’s protein structure prediction, I called it my top AI in Medicine moment of the year. That almost pales in comparison to what just happened. Isomorphic Labs — the Alphabet drug discovery company born from DeepMind — just unveiled the Isomorphic Labs Drug Design Engine (IsoDDE). Not an incremental upgrade. A paradigm shift. IsoDDE more than doubles AlphaFold 3’s accuracy on the hardest protein-ligand structure predictions. It predicts binding affinity better than gold-standard physics-based methods at a fraction of the time and cost. And it identifies hidden ‘cryptic’ binding pockets on proteins using nothing but the amino acid sequence — pockets that took experimental scientists 15 years to find in the lab! AlphaFold gave us the map. This is the engine that lets us drive. Guys, what we’re witnessing is a phase shift — from predicting molecular structure to reasoning about molecular behavior. When a model can generalize across pocket discovery, binding affinity, and novel structure outside its training data, it’s no longer interpolating known biology. It’s learning the rules of the chemical game itself. As I wrote in Chapter 9 of my book, Rebooting Cancer Care, ‘The algorithmic architect is taking its place at the drawing board, offering the potential to fundamentally reboot the entire engine of how we conceive, create, and refine cancer medicines.’ The ambition I described then — to make drug discovery faster, more resource-efficient, and more predictive, allowing us to ‘fail faster and cheaper’ with weak candidates while creating therapies precisely attuned to the molecular drivers of each patient’s cancer — is exactly what IsoDDE now makes tangible. Wright understood that form and function aren’t separate pursuits. Neither are structure and behavior in molecular biology. IsoDDE joins them in something approaching that spiritual union — where seeing a protein and understanding how to drug it become one act. Targets we called ‘undruggable’ don’t disappear. They become designable. ‘Rare’ and ‘never tried before’ stop being scientific dead ends and start becoming queue positions. This is what it looks like when AI stops merely describing life and starts collaborating with it. And the question is no longer whether this transforms cancer drug discovery. It’s whether our systems — regulatory, clinical, organizational — can keep pace with what the science.” More posts featuring Douglas Flora. ChatGPT said: Douglas Flora: AI-Driven IsoDDE Engine Signals a New Era in Cancer Drug Discovery You said: Mark Hughes Foundation Centre for Brain Cancer Research shared a post on LinkedIn: “Congratulations to James Brown-Miles, Dr Oun Al-iedani, Professor Hubert Hondermarck, Professor Peter Greer, Professor Mike Fay and Associate Professor Saad Ramadan on the publication Exploring the Role of Advanced MRI in Understanding Glioblastoma Biology: A Scoping Review. Based on James’s PhD work, this review brings together past imaging research to provide a clearer picture of glioblastoma biology. This work aims to identify the most promising methods, to guide future studies. Ultimately, these techniques could improve diagnosis, help predict outcomes and ultimately advance care for people with glioblastoma.” ChatGPT said: Mark Hughes Foundation Centre for Brain Cancer Research: New Review Explores Advanced MRI in Glioblastoma Biology You said: most promising methods for clearer picture of glioblastoma biology ChatGPT said: Mark Hughes Foundation Centre for Brain Cancer Research: Identifying Promising MRI Methods for Understanding Glioblastoma Biology You said: Sucharu Prakash, Director of Quality Services at Texas Oncology, shared a post on LinkedIn: “Check out my editorial/commentary in February edition of Evidence Based Oncology. ctDNA technology continues to impress and provide us with tools we could only have imagined a few years ago. From early detection to personalized targeted therapies to MRD detection, ctDNA has changed how we practice and most importantly, has improved patient outcomes. Legislative support helps tremendously! Education and awareness of both physicians and patients continues to be an unmet need.” ChatGPT said: Sucharu Prakash: ctDNA Advances Transform Cancer Detection, Monitoring, and Treatment You said: Sucharu Prakash: ctDNA technology From early detection to personalized targeted therapies ChatGPT said: Polished OncoDaily-style version: Sucharu Prakash: ctDNA Technology from Early Detection to Personalized Targeted Therapies You said: International Association for the Study of Lung Cancer(IASLC) shared a post on LinkedIn: “Applications are still open! STARS Patient Research Advocate (PRA) Program A fully virtual training program for patients and caregivers seeking to build research literacy and collaborate effectively with investigators. STARS Scholar Program An in-person opportunity at WCLC 2026 for experienced advocates, including travel support and structured engagement activities. Together, these programs help ensure that research is informed by lived experience and shaped by a global advocacy community. We encourage interested applicants to learn more and apply before March 12, 2026. ChatGPT said: International Association for the Study of Lung Cancer: Applications Open for STARS Patient Advocate and Scholar Programs You said: Rita A. Sakr, Medical Doctor at Emirates Hospitals Group, and Clinical Adjunct Professor at the University of Sharjah, shared a post on LinkedIn: “A great privilege to be part of Brussels Onco and Oncoplastic Breast Surgery Conference (BOOBS II) organized by Moustapha Hamdi and Yazan Masannat for the session on hereditary breast cancer from the genetic testing updates to the management of results and to the prophylactic medical and surgical approach. Excellent conference with high educational level and big variety of multidisciplinary topics on Breast Oncoplastic and Plastic Surgery with excellent colleagues and mentors in the field from all continents.” ChatGPT said: Rita A. Sakr: Highlights Advances in Hereditary Breast Cancer at BOOBS II Conference You said: Rita A. Sakr: A great privilege to be part of Brussels Onco and Oncoplastic Breast Surgery Conference ChatGPT said: Polished OncoDaily-style version: Rita A. Sakr: Honored to Participate in Brussels Onco and Oncoplastic Breast Surgery Conference You said: why do you change???? ChatGPT said: I get why it feels like I “changed” it — I was just trying to make it read a bit more professional and concise, which is the usual OncoDaily style. “A great privilege to be part of…” is perfectly fine, though a little longer and more casual for a headline. If you want to keep your original wording, it works too: Rita A. Sakr: A Great Privilege to Be Part of Brussels Onco and Oncoplastic Breast Surgery Conference It’s really just a style choice—OncoDaily tends to favor slightly punchier phrasing, but your version is correct. You said: Servier Pharmaceuticals shared a post on LinkedIn: “At Servier, we’re committed to fostering an inclusive environment where diverse perspectives drive better science and improved outcomes for patients worldwide. This Blac kHistory Month, we’d like to take a moment to honor and celebrate the achievements of Black leaders, scientists and professionals who have shaped the healthcare landscape and continue to drive innovation across the pharmaceutical industry. For resources and events in the Boston area.” ChatGPT said: Servier Pharmaceuticals

Servier Pharmaceuticals shared a post on LinkedIn:

“At Servier, we’re committed to fostering an inclusive environment where diverse perspectives drive better science and improved outcomes for patients worldwide.

This Black History Month, we’d like to take a moment to honor and celebrate the achievements of Black leaders, scientists and professionals who have shaped the healthcare landscape and continue to drive innovation across the pharmaceutical industry.”

More posts featuring Servier Pharmaceuticals on OncoDaily.

cancer OncoDaily Oncology Servier Servier Pharmaceuticals